View sample alerts with expert analyses from the inThought team.
MODERATE IMPACT Ipsen will present 26 abstracts at TOXINS 2021. A key presentation titled AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations demonstrates long-duration of Dysport. Data from the long-term open-label extension study indicated that repeat cycles of Dysport resulted in at least 12 weeks duration for a large proportion of study patients for […]
November 19, 2020 Impact: High Results for Affimed’s AFM13 (CD30/CD16A ICE; Innate Cell Engager) in combination with Keytruda (pembrolizumab) in a phase 1b study for r/r Hodgkin Lymphoma patients have been published in the journal Blood. Key efficacy data included (n=30): ORR (Objective Response Rate): 88% (CR rate: 46%) at the recommended dose level Investigators deemed […]
November 10, 2020 Impact: Moderate Oramed is planning two new phase 2 studies to evaluate the efficacy and safety of its oral insulin candidate, ORMD-0801 in T2DM patients with NASH. The studies are due to start in November 2020. The first study is a double-blind study that will randomize 36 subjects in a 2:1 ratio to […]
October 8, 2020 Impact: Moderate Krystal Biotech announced the presentation of preclinical data supporting the ongoing development of KB301. Data will be presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting to be held October 9-11, 2020. KB301 is an investigational therapy designed to restore collagen homeostasis locally via directed expression of […]
September 15, 2020 Impact: Moderate At two recent investor conferences, Revance Therapeutics’ CEO, Mark Foley, provided updates on the company’s activities.
September 21, 2020 Impact: High inThought Research and Bloomberg Intelligence were joined by expert speakers in the field of Spinal Muscular Atrophy (SMA), Adrian Krainer, PhD, and Thomas Crawford, MD, to discuss the recent approval of the third disease-modifying therapy, Evrysdi. Key insights provided include: Patients currently stable with Zolgensma or Spinraza will likely not […]